arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BIO-PATH HOLDINGS, INC.

BPTH
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
24 Metrics
Absolute Benchmarks
Price Chart
55
Health
Fair
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, BIO-PATH HOLDINGS, INC. shows weak fundamentals, weighed down by Return on Invested Capital. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC 2.8%
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$37.00K
↑ +184.6% —
Net Income Profit after all expenses
$-270.00K
↑ +90.5% —
FCF / Share Free cash flow per share
$-0.03
↑ +98.7% —
Long-Term Debt Long-term obligations
$0.00
— —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -7787.0% is weak on an absolute basis (target > 10%)

Health Breakdown

Cash Quality ↑
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 67 quarters